België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ibsa farmaceutici italia s.r.l. - eicosapentaeenzuur 460 mg; docosahexaeenzuur 380 mg; d-alfa-tocoferol 4 mg - capsule, zacht - 1000 mg - eicosapentaeenzuur 460 mg; docosahexaeenzuur 380 mg; d-alfa-tocoferol 4 mg - omega-3-triglycerides incl. other esters and acids

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

narodowe centrum badan jadrowych pl - hynic-[d-phe1,tyr3-octreotide]-trifluoracetaat 20 µg - kit voor radiofarmaceutisch preparaat - 20 µg - hynic-[d-phe1,tyr3-octreotide]-trifluoracetaat 20 µg - technetium (99mtc) hynic-octreotide

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ibsa farmaceutici italia s.r.l. - eicosapentaeenzuur 460 mg; docosahexaeenzuur 380 mg; d-alfa-tocoferol 4 mg - capsule, zacht - omega-3-triglycerides incl. other esters and acids

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ferring b.v. polarisavenue 130 2132 jx hoofddorp - corticoreline trifluoracetaat samenstelling overeenkomend met ; ; corticoreline (humaan) 100 µg/ampul - poeder en oplosmiddel voor oplossing voor injectie - natriumchloride ; water, gezuiverd ; zoutzuur (e 507), - corticorelin

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

splendris pharmaceuticals gmbh frankfurter strasse 39 63303 dreieich (duitsland) - bivalirudine 2-trifluoracetaat 276 mg/flacon samenstelling overeenkomend met ; bivalirudine 250 mg/flacon - poeder voor oplossing voor injectie of infusie - mannitol (d-) (e 421) ; natriumhydroxide (e 524) ; stikstof (head space) (e 941)

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

adoh b.v. godfried bomansstraat 31 6543 ja nijmegen - bivalirudine x-trifluoracetaat samenstelling overeenkomend met ; ; bivalirudine 250 mg/flacon - poeder voor concentraat voor oplossing voor injectie / infusie - mannitol (d-) (e 421) ; natriumhydroxide (e 524) ; stikstof (head space) (e 941)

Europese Unie - Nederlands - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Europese Unie - Nederlands - EMA (European Medicines Agency)

zoetis belgium sa - geïnactiveerd schmallenberg-virus, stam bh80 / 11-4 - immunologicals voor bovidae, geïnactiveerde virale vaccins - cattle; sheep - voor actieve immunisatie van rundvee en schapen vanaf 3. 5 maanden oud om viremie te voorkomen die is geassocieerd met infectie door het schmallenberg-virus.

Europese Unie - Nederlands - EMA (European Medicines Agency)

ecuphar nv - enflicoxib - ontstekingsremmende en antireumatische producten - honden - for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.